Source: www.reuters.com
Author: staff

Danish biotechnology firm Genmab said on Thursday:
– The U.S. Food and Drug Administration lifted a partial clinical hold on zalutumumab studies being conducted under a U.S. Investigational New Drug application.

– Enrolment of patients can now resume in the Phase II study in patients with head and neck cancer considered incurable with standard treatment and the Phase I/II frontline study of zalutumumab in combination with chemo-radiation.

Note:
1. Reporting by Copenhagen newsroom